INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: Six Years Outcome. Issue 12 (December 2015)

• Record Type: Journal Article
• Authors: Ruiz-Moreno, Jose M.; Montero, Javier A.; Araiz, Javier; Arias, Luis; García-Layana, Alfredo; Carneiro, Angela; Figueroa, Marta S.; Silva, Rufino
• Is Part Of: Retina. Volume 35:Issue 12(2015:Dec.)
• Publication Date: 2015-12
• Subjects: bevacizumab -- choroidal neovascularization -- high myopia -- ranibizumab; Retina -- Diseases -- Periodicals; Retinal Diseases; Vitreous Body; 617.735
• DOI: 10.1097/IAE.0000000000000632
• Languages: English
• ISSNs: 0275-004X

Abstract

Abstract : Purpose: To report the visual outcome after 6-year follow-up in highly myopic eyes with choroidal neovascularization treated with anti-vascular endothelial growth factor drugs. Methods: Retrospective, nonrandomized, multicenter, consecutive, and interventional case series. Results: Seventy-eight patients were treated with intravitreal bevacizumab and 19 with ranibizumab. Mean age of the patients was 56.5 years (SD, 13.3). The average number of letters read was 56.7 (SD, 19.0) at baseline; 65.7 (SD, 18.4) at 12 months; 63.6 (SD, 20.6) at 24 months; 62.4 (SD, 21.4) at 36 months; 60.6 (SD, 22.0) at 48 months; 58.9 (SD, 22.9) at 60 months, and 58.4 (SD, 22.7) at 72 months ( P < 0.01, between initial vs. 12, 24, and 36 months; P = 0.07, 0.3, and 0.5 between initial vs. 48, 60, and 72 months, respectively; Student's t -test paired data). The mean total number of intravitreal injections was 3.3 (SD, 2.3; range, 1–9). Conclusion: Bevacizumab and ranibizumab are effective therapies and show similar clinical effects in myopic eyes with choroidal neovascularization. Visual acuity gain is maintained at a 3-year follow-up. The improvement is no longer statistically significant at Years 4, 5, and 6. Abstract : Intravitreal anti-vascular endothelial growth factor treatment is effective in the treatment of myopic choroidal neovascularization, and its efficacy is not related to the type of drug used or the initial treatment regime. Visual acuity gain decreases after Year 4.